Ono picks up Japan Relistor rights
This article was originally published in Scrip
Onohas acquired exclusive Japanese rights to develop and commercialiseProgenics Pharmaceuticals' mu-opioid receptor antagonist Relistor (methylnaltrexone bromide), for $15 million up front and up to $20 million in development milestones. Ono will also pay sales-based royalties that analysts say could exceed the rate paid by Wyeth, Progenics' partner for Relistor outside Japan, and commercialisation milestones, which could be worth up to a further $20 million.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.